Antiphospholipid Syndrome (APS) is associated with abnormal blood clotting in patients with antiphospholipid antibodies (aPL). Some of the clinical problems in APS patients include clots in veins or arteries, pregnancy losses, skin changes, low platelet counts, and heart valve abnormalities. Patients with APS and history of thrombosis usually require long-term anticoagulation (blood thinners). APS can occur in combination with another systemic autoimmune disease, most commonly systemic lupus erythematosus, or can occur without any other associated condition. APS diagnosis requires at least two positive blood (aPL) tests that should be spaced at least 3 months apart. The most commonly used tests to detect aPL are lupus anticoagulant test, anticardiolipin antibody test, and anti-Beta-2 glycoprotein-I test. The Antiphospholipid Syndrome (APS) Clinical Research Task Force (CRTF) was one of six task forces developed by the organization committee of the 13th International Congress on Antiphospholipid Antibodies (aPL), which was held in Galveston, Texas in April 2010. The task force recommended that there is an urgent need for a true international collaborative approach to design and conduct well-designed prospective large-scale multi-center clinical trials of patients with persistent and clinically significant aPL profiles.1 Thus, an international collaborative working meeting took place in Miami (Nov 2-4, 2010) that resulted in the formation of a clinical trial research alliance entitled: AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking ("APS ACTION"). 1Erkan D, Derksen R, Levy R, Machin S, Ortel T, Pierangeli S, Roubey R, Lockshin MD. Antiphospholipid Syndrome Clinical Research Task Force Report. Lupus 2011;20:219-224